Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Aquilo Capital Management, LLC

Q1 2025 · 13F-HR

Aquilo Capital Management, LLCholdings as filed

Filed 2025-05-15 · accession 0001591986-25-000004

$55.8M
Reported value
13
Positions
2025-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
031162100AMGNAMGEN INC$18.7M33.5%60,000CALLNONE
09627Y1092655787DBLUEPRINT MEDICINES CORP$7.4M13.3%83,926CommonSOLE
04280A100ARWRARROWHEAD PHARMACEUTICALS IN$7.0M12.6%550,130CommonSOLE
74366E102PTGXPROTAGONIST THERAPEUTICS INC$4.0M7.08%81,692CommonSOLE
501575104KYMRKYMERA THERAPEUTICS INC$3.8M6.80%138,521CommonSOLE
74019P207DTILPRECISION BIOSCIENCES INC$3.5M6.21%726,149CommonSOLE
04335A105ARVNARVINAS INC$2.5M4.54%360,766CommonSOLE
75901B107RGNXREGENXBIO INC$1.9M3.48%271,302CommonSOLE
007002108TORCEURADICET BIO INC$1.9M3.32%2,456,194CommonSOLE
088786108BCYCBICYCLE THERAPEUTICS PLC$1.5M2.61%171,695CommonSOLE
N44445109IMTXIMMATICS N.V$1.4M2.47%304,902CommonSOLE
760273102RPTXREPARE THERAPEUTICS INC$1.3M2.29%1,293,715CommonSOLE
98985Y108ZYMEZYMEWORKS INC$1.0M1.80%84,482CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.